A Bristol Myers-backed biotech wants to treat heart disease with non-coding RNAs. It's one step closer to proof-of-concept

Max Gelman

Senior Editor

Is it possible to use strands of non-coding RNA, a burgeoning therapeutic area that researchers now believe plays an important part in how similar genes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A Bristol Myers-backed biotech wants to treat heart disease with non-coding RNAs. It's one step closer to proof-of-concept

Max Gelman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Vertex makes money from sickle cell therapy Casgevy

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

A Bris­tol My­ers-backed biotech wants to treat heart dis­ease with non-cod­ing RNAs. It's one step clos­er to proof-of-con­cept

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

A Bristol Myers-backed biotech wants to treat heart disease with non-coding RNAs. It's one step closer to proof-of-concept